Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00127010
Recruitment Status : Completed
First Posted : August 5, 2005
Last Update Posted : September 26, 2016
Information provided by (Responsible Party):

August 4, 2005
August 5, 2005
September 26, 2016
November 2005
Not Provided
Antibody levels after vaccination
Same as current
Complete list of historical versions of study NCT00127010 on Archive Site
Safety of the study vaccines
Safety of the study vacccines
Not Provided
Not Provided
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
This study included an active control group who received the licensed Priorix (measles, mumps, rubella [MMR] vaccine).
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • Measles
  • Rubella
  • Mumps
  • Varicella
Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
Other Names:
  • Measles
  • Mumps
  • Rubella and Chickenpox (live vaccine)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
June 2006
Not Provided

Inclusion Criteria:

  • A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.

Exclusion Criteria:

  • History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
  • Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination
Sexes Eligible for Study: All
11 Months to 13 Months   (Child)
Contact information is only displayed when the study is recruiting subjects
Belgium,   Germany,   Netherlands
Not Provided
Not Provided
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through following the timelines and process described on this site.
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP